ARPA-H funds on-demand, patient-specific RNA medicines with $125M grant
The U.S. ARPA-H is awarding $125 million to enable the rapid, on-demand production of personalized RNA-based therapies, accelerating the development of patient-specific genetic medicines; five groups have been selected for funding.